Efficacy and safety of botulinum neurotoxin type A (Xeomin®) in the treatment of facial expression frown lines;Wirksamkeit und Sicherheit von Botulinum Neurotoxin Typ A (Xeomin®) in der Behandlung der Glabellafalte

Kosmetische Medizin

Volumn 29, Issue 3, 2008, Pages 148-151

  Schleyer, Verena ^a   Berneburg, Mark ^b  

^a KLINIKUM AUGSBURG   (Germany)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Botulinum neurotoxin type A; Facial expression frown lines; Xeomin

Indexed keywords

EID: 48649091722     PISSN: 14304031     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Berardelli A, Abbruzzese G, Bertolasi L, Cantarella G, Carella F, Currà A, De Grandis D, DeFazio G, Galardi G, Girlanda P, Livrea P, Modugno N, Priori A, Ruoppolo G, Vacca L, Manfredi M (1997) Guidelines for the therapeutic use of botulinum toxin in movement disorders. Italian Study Group for Movement Disorders, Italian Society of Neurology. Ital J Neurol Sci 18: 261-9.
2. Ascher B, Zakine B, Kestemont P, Baspeyras M, Bougara A, Santini J. A (2004) multicenter, randomized, double blind, placebo-controlled study of efficacy and safety of three doses of botulinumtoxin A in the treatment of glabellar lines. J Am Acad Dermatol 51: 223-233.
3. Carruthers JD, Lowe NJ, Menter MA, Gibson J, Eadie N (2003) for the Botox Glabellar Lines II Study Group. Double-blind, placebo-controlled study of the safety and efficacy of botulinum toxin type A for patients with glabellar lines. Plast Reconstr Surg 112: 1089 98.
4. Rzany B, Ascher B, Fratila A, Monheit GD, Talarico S, Sterry W for the GLADYS Study Group (2006) Efficacy and Safety of 3- and 5-injection patterns (30 and 50 U) of Botulinum toxin A (Dysport) for the treatment of wrinkles in the glabella and the central forehead region. Arch Dermatol 42: 320-326.
5. Sommer Boris, Bergfeld D, Sattler G (2007) Konsensusempfehlungen zum Gebrauch von Botulinumtoxin A in der ästhetischen Medizin - Klinische Erfahrungen und Empfehlungen langjähriger Anwender. JDDG 5 Suppl 1: S1-S29.
6. Carruthers J, Fagien S, Matarasso SL, and the Botox Consensuns Group (2004) Consensusrecommendations on the use of botulinum toxine type A in facial aesthetics. Plast Recconstr Surg 114 (Suppl 6): 1-22.
7. Jost WH, Blumel J, Grafe S (2007) Botulinum neurotoxin type A free of complexing proteins (Xeomin®) in Facial Dystonia. Drugs 67: 669-83.
8. Maack M, Krüger J, Bayrhammer J, Reuther T, Kerscher M (2007) Beeinflussen Komplexproteine das Diffusionsverhalten. Dtsch Derm 8: 562-3.
9. Fritsch C (2006) Wirksamkeit des neuen, komplexproteinfreien Botulinumtoxins (Xeomin®) in der Therapie mimischer Lachfalten. Kosmet Med 3: 124-129.
10. Carruthers A, Carruthers J, Cohen J (2003) A prospective, double blind, randomized, parralel-group, dose-ranging study of botulinum toxin type A in female subjects with horizontal forehead rhytides. Dermatol Surg 29: 461-46.
11. Carruthers JD, Lowe N J, Menter MA, Gibson J, Nordquist M, Mordaunt J, et al. (2002) A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines. J AM Acad Dermatol 46: 840-9.
12. Khorram R (2006) Faltentherapie mit einem neuen deproteinisierten Botulinumtoxin A (Xeomin®) bei 40 Probandinnen. Plast Chir Suppl. 1: 55.
13. Prager W, Zschocke I, Turnbull K, Steinkraus V (2007) Wirksamkeit und Verträglichkeit des neuen, komplexproteinfreien Botulinumtoxins (Xeomin®) bei der Behandlung von mimischen Falten - Untersuchungsergebnisse. Kosmet Med 2: 81-84.
14. Heckmann M, Rzany B, eds. (2006) Botulinumtoxin in der Dermatologie: Grundlagen und Praktische Anwendung. München, Germany: Urban und Vogel.